UNITED THERAPEUTICS Corp
For the period ended Jun 30, 2026. Filed Aug 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 5, 2026
UTHR$588.61+1.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Cash Flows
| Six Months Ended June 30, | ||
|---|---|---|
| 2026 | 2025 | |
| (Unaudited) | ||
| Cash flows from operating activities: | ||
| Net income | $607.9 | $631.7 |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||
| Depreciation and amortization | 46.8 | 40.9 |
| Share-based compensation expense | 77.3 | 69.6 |
| Impairment of property, plant, and equipment | — | 21.7 |
| Net unrealized losses on equity securities | 48.2 | 9.3 |
| Deferred income taxes | 51.6 | — |
| Other | 56.8 | 4.7 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | 39.9 | (100.0) |
| Inventories | (57.8) | (18.6) |
| Accounts payable and accrued expenses | (16.7) | 43.5 |
| Other assets and liabilities | (77.1) | (49.9) |
| Net cash provided by operating activities | 776.9 | 652.9 |
| Cash flows from investing activities: | ||
| Purchases of property, plant, and equipment | (208.8) | (137.1) |
| Deposits | (6.4) | (9.8) |
| Purchases of available-for-sale debt securities | (770.8) | (2,499.2) |
| Maturities of available-for-sale debt securities | 534.3 | 915.9 |
| Sales of available-for-sale debt securities | 1,307.9 | 1,265.6 |
| Purchase of investment in privately held company | (25.0) | — |
| Net cash provided by (used in) investing activities | 831.2 | (464.6) |
| Cash flows from financing activities: | ||
| Payments to repurchase common stock | (1,500.0) | — |
| Proceeds from line of credit | — | 200.0 |
| Repayment of line of credit | — | (500.0) |
| Excise tax paid on net share repurchase | — | (5.0) |
| Payments of debt issuance costs | (3.4) | (11.5) |
| Proceeds from the exercise of stock options | 194.6 | 34.7 |
| Proceeds from the issuance of stock under ESPP | 5.6 | 4.9 |
| RSUs withheld for taxes | (58.8) | (15.5) |
| Net cash used in financing activities | (1,362.0) | (292.4) |
| Net increase (decrease) in cash and cash equivalents | $246.1 | $(104.1) |
| Cash and cash equivalents, beginning of period | 1,557.1 | 1,697.2 |
| Cash and cash equivalents, end of period | $1,803.2 | $1,593.1 |
| Supplemental cash flow information: | ||
| Cash paid for interest | $3.8 | $9.6 |
| Cash paid for income taxes | $102.5 | $253.9 |
| Non-cash investing and financing activities: | ||
| Non-cash additions to property, plant, and equipment | $104.1 | $66.2 |
| Excise tax on net share repurchase | $5.4 | $— |
| 8 | United Therapeutics, a public benefit corporation |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.